It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

Tis the season of snow and twinkling lights. The time for eating rich food and buying stuff. Lots of stuff. If the thought of ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact ...

CVS announced Friday that CEO Karen Lynch will be replaced by David Joyner, as consumer spending drops at the company's retail pharmacies and Aetna, its insurance unit, faces higher medical costs.

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

Behind negative returns for shares of American Express and Merck, the Dow Jones Industrial Average is declining Friday morning.